Lung Cancer in Men

How Symptoms, Causes, Treatment, and Outcomes Differ

Table of Contents
View All
Table of Contents

Lung cancer in men differs from lung cancer in women in a number of ways. The chance of a female smoker developing lung cancer is higher than a male smoker, but overall more men develop lung cancer simply due to the fact that men are more likely to smoke. Researchers are not entirely sure why this is, but it is believed that genetic factors and biological susceptibility between the sexes may explain the disparity.

The types of lung cancer that commonly affect men also differ, as does the effectiveness of therapies used to treat them. Generally speaking, the outcomes in men tend to be poorer, although newer targeted drugs and immunotherapies show promise in terms of improving survival times.

An elderly man talking to his doctor about some recent test results.
 Tom Werner/DigitalVision/Getty Images


Lung cancer is the leading cause of cancer deaths in men, both in the United States and worldwide. Though men are historically more likely to develop the disease than women, the number of men and women diagnosed each year has been slowly reaching parity.

According to 2020 statistics issued by the American Cancer Society:

  • Around 228,820 new cases of lung cancer are projected to be diagnosed in the United States (comprised of 116,300 men and 112,520 women).
  • Around 135,720 Americans will die from lung cancer, 72,500 of whom will be men and 63,220 of whom will be women.

In the United States, smoking and non-smoking men have a one in 15 lifetime risk of getting lung cancer compared to women, who have a one in 17 risk. Even so, the pattern of risk varies significantly—and sometimes dramatically—between the two sexes.

However, for reasons that are not entirely understood, men who smoke are less likely to develop the disease than their female counterparts. A 2014 study published in the British Journal of Cancer reported that men who are heavy smokers are 50% less likely to develop the types of lung cancers associated with tobacco smoke.

The same appears to be true of men who have never smoked. Compared to never-smoking women, never-smoking men are around 33% less likely to get lung cancer—a disparity believed to be associated with female genetics, body size, and exposure to carcinogens in the home, such as radon. Even so, male never-smokers who get lung cancer are at greater risk of death than women.

Most Common Types in Men

Men are more likely to get squamous cell lung cancer, a type of non-small cell lung cancer (NSCLC) that develops within the airways of the lungs. It accounts for around 30% of all NSCLC diagnoses and is directly linked to cigarette smoke.

By contrast, lung adenocarcinomas, the type of NSCLC that develops in the periphery of the lungs, predominate in women and non-smokers.

Men are somewhat less likely to get small cell lung cancers (SCLC), a less common but generally more aggressive form of the disease. A 2012 review of studies in the journal Lung Cancer reported that SCLC accounts for up to 20% of lung cancer cases in men versus 34% in women.

However, when heavy smoking is added to the mix, the risk of these diseases can start to equalize.

Men who smoke more than 30 cigarettes per day increase their odds of squamous cell lung carcinoma 100-fold, lung adenocarcinoma 22-fold, and SCLC 111-fold.

A similar pattern is seen in women, wherein smoking over 30 cigarettes daily increases the odds of squamous cell lung carcinoma 63-fold, lung adenocarcinoma 17-fold, and SCLC 109-fold.

Lung Cancer Symptoms in Men

A man who gets a certain type of lung cancer will generally have the same symptoms as a woman who gets the same type. However, because men are more likely to get squamous cell lung cancer, they often exhibit symptoms more profoundly because that kind of tumor lodges itself within the airways rather than the outer edges of the lungs (as occurs with lung adenocarcinoma).

Common symptoms of squamous cell cancer include:

Although these same symptoms can occur with lung adenocarcinoma, many of the more tell-tale signs (such as coughing up blood or wheezing) occur when the tumor has spread (metastasized) from the outer edges to the central airways.

With squamous cell carcinoma, these can occur even before the tumor has metastasized.


Though smoking is considered the cause of lung cancer in 70% to 80% of women with the disease, it accounts for around 90% of cases in men. The difference in incidence can be largely attributed to the rates of smoking, wherein 17.5% of American men are smokers compared to only 13.5% of American women. Other factors can also contribute to cases in men.

According to a 2017 study in BMC Public Health, occupational exposure to carcinogens accounts for as many as 13% to 29% of lung cancer cases in men. Asbestos is among the main culprits alongside arsenic, benzene, cadmium, coal tar, diesel fuel emissions, formaldehyde, and medical radiation.

Occupations linked to the occupational risk include metal workers, painters, cleaners, bakers, plumbers and pipefitters, welders, freight handlers, and construction workers.

It is important to note that many men who get lung cancer are not current smokers. In fact, roughly 40% were former smokers at the time of their diagnoses. Compared to never-smokers, men who are former smokers have a four-fold increased risk of lung cancer. Women who are former smokers have a roughly 3.5-fold risk.

Should You Be Screened?

If you are a heavy smoker with a long history of smoking, speak with your healthcare provider to see if you are a candidate for annual lung cancer screening.

The U.S. Preventive Services Task Force recommends screening for adults between 50 to 80 who have a smoking history of 20 pack-years or more and are either currently smoking or quit within the past 15 years.


There are different treatments available for people diagnosed with lung cancer. Many of the traditional approaches—including surgery, chemotherapy, and radiation—do not differ between men and women.

Targeted Therapies

Targeted therapies are drugs designed to recognize, target, and kill cells with specific genetic mutations. These include mutations such as epidermal growth factor receptor (EGFR) gene and the anaplastic lymphoma kinase (ALK) gene.

Women tend to have these specific mutations more than men. As a result, certain targeted drugs like EGFR inhibitors—which include Tagrisso (osimertinib)—are 25% less effective in men. Other drugs like ALK inhibitors appear to work equally well.


In 2015, immunotherapies were introduced as a novel treatment for lung cancer. These include two drugs classified as PD-1 inhibitorsOpdivo (nivolumab) and Keytruda (pembrolizumab)—that boost the body's immune response to cancer by blocking the programmed death-1 (PD-1) protein. Unlike targeted therapies that recognize specific mutations, immunotherapies respond to the degree of mutations.

According to a 2016 study in Oncotarget, while women have more targetable mutations than men, men have a higher overall tumor mutation burden (TMB). Cells that have multiple gene mutations (i.e, a high TMB) are more likely to be recognized as abnormal and attacked by the body's immune system.

Because of this, PD-1 inhibitors tend to be more effective in men. According to a 2018 study in ESMO Open, PD-1 inhibitors prolonged disease-free survival in men compared to chemotherapy but showed little to no benefit in a matched set of women with lung cancer.


The survival rate, the percentage of people alive after a specific period, can vary by the stage and type of lung cancer involved as well as a person's sex. The current data shows that the survival rate in men is lower than for women at all stages of the disease.

For men, the overall five-year survival rate is only around 16% (compared to 23% in women). This is due in part to delayed diagnoses in men who generally tend to put off seeing a healthcare provider until overt symptoms appear.

A 2019 study in Thoracic Cancer reported that being male, a current smoker, and over age 65 are the top three factors associated with delayed diagnoses in people with lung cancer.

Overall, men with NSCLC have a 27% higher risk of death than women. They also experience shorter survival times with SCLC (six months versus nine months, respectively).


Generally speaking, men with lung cancer report higher quality of life compared to women, in part because they tend to cope better with treatment and may be less emotionally impacted by things like hair loss. Even so, this shouldn't infer that men can carry the burden of the disease "better" or that all men are the same.

Studies have shown that men with lung cancer can experience isolation, depression, and anxiety as well as feelings of shame, stigma, and discrimination almost as much as women.

Seeking out in-person or online support groups can help ease these burdens by providing interaction with others who have a firsthand understanding of the disease. In fact, men can benefit as equally as women from support groups and counseling.

A Word From Verywell

In the end, there is no such thing as "men's lung cancer" and "women's lung cancer." However, there are variations in risk, treatment responses, and help-seeking behaviors that can impact survival and long-term outcomes in men.

Men can improve these outcomes by identifying their risk of lung cancer, including smoking and hazards in the workplace.

19 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Hellyer JA, Patel MI. Sex disparities in lung cancer incidence: Validation of a long-observed trend. Transl Lung Cancer Res. 2019;8(4):543-5. doi:10.21037/tlcr.2019.04.06

  2. American Cancer Society. Key statistics for lung cancer.

  3. Planchard D, Besse B. Lung cancer in never-smokers. Eur Respir J. 2015;45(5):1214-7. doi:10.1183/09031936.00046915

  4. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer—elative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210-9. doi:10.1002/ijc.27339

  5. Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer (Auckl). 2012;3:79-89. doi:10.2147/LCTT.S37319

  6. Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811-5.

  7. American Lung Association. Women and tobacco use.

  8. Delva F, Margery J, Laurent F, et al. Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendationsBMC Public Health. 2017;17:191. doi:10.1186/s12889-017-4114-1

  9. O'Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611. doi:10.1136/bmjopen-2018-021611

  10. US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation StatementJAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117

  11. Pinto JA, Vallejos CS, Raez LE, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open. 2018;3(3):e000344. doi:10.1136/esmoopen-2018-000344

  12. Xiao D, Pan H, Li F, Wu K, Zhang X, He J. Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget. 2016. 7(16):22857-22864. doi:10.18632/oncotarget.8213

  13. Cao D, xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8(9):e1629258. doi:10.1080/2162402X.2019.1629258

  14. American Society of Clinical Oncologists. Lung cancer - Non-small cell. In:

  15. Leiro-Fernández V, Mouronte-Roibás C, García-Rodríguez E, et al. Predicting delays in lung cancer diagnosis and staging. Thorac Cancer. 2019;10(2):296-303. doi:10.1111/1759-7714.12950

  16. Lim JH, Ryu JS, Kim JH, Kim HJ, Lee D. Gender as an independent prognostic factor in small-cell lung cancer: Inha Lung Cancer Cohort study using propensity score matching. PLoS ONE. 2018;13(12):e0208492. doi:10.1371/journal.pone.0208492

  17. Polanski J, Jankowska-Polanska B, Rosinczuk J, Chabowski M, Szymanska-chabowska A. Quality of life of patients with lung cancer. Onco Targets Ther. 2016;9:1023-8. doi:10.2147/OTT.S100685

  18. Chambers SK, Baade P, Youl P, et al. Psychological distress and quality of life in lung cancer: the role of health-related stigma, illness appraisals and social constraints. Psychooncology. 2015;24(11):1569-77. doi:10.1002/pon.3829

  19. Maclean A, Hunt K, Smith S, Wyke S. Does gender matter? An analysis of men's and women's accounts of responding to symptoms of lung cancer. Soc Sci Med. 2017;191:134-42. doi:10.1016/j.socscimed.2017.09.015

By Lynne Eldridge, MD
 Lynne Eldrige, MD, is a lung cancer physician, patient advocate, and award-winning author of "Avoiding Cancer One Day at a Time."